Home › Optic Nerve Disorders › NCT07623668
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)
Who can join
Ages 18 to 50 · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. * Onset of visual loss symptoms in the previous 12 days before first administration of study treatment. Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety
About the study
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
What is being tested
- Privosegtor (drug)
- Methylprednisolone (drug)
- Placebo (other)
Sponsor: Oculis · Participants: 210 · Started: May 28, 2026
Contact the study team
- Chief Development Officer · Phone: 617-928-5886
Official record on ClinicalTrials.gov — NCT07623668
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.